The second institutional initiative included in the 2016-2021 strategic plan aims to position the IRCM as a leader in the discovery of biomarkers and their application as diagnostic tools to improve the treatment of diseases and accelerate the discovery of efficient and safer drugs for the population.
Designated by the acronym OBPI (Open Biomarker Profiling Initiative), this project aims to profile a large number of biomarkers associated with various diseases in patient cohorts, and to disseminate the results, very shortly after obtaining them, to the scientific community through open access. Several researchers at the IRCM, in Quebec and in Canada already take part in OBPI, which will be used to spearhead similar projects in the near future.
Thanks to targeted industrial partners, the OBPI project at the IRCM will lead to the commercialization of efficient diagnostic tools that will maximize the efficacy of numerous therapies.
By opting to disseminate its result in open access, the IRCM is taking on a national and international leadership role in a type of scientific communication that promotes collaboration and mutual aid. The rapid dissemination of results will allow, on one hand, to accelerate the development of safe drugs and, on the other hand, to reduce healthcare costs by identifying in advance the patients most likely to benefit from a treatment.
This initiative reaffirms the IRCM’s desire to have a major impact on the development of tomorrow’s medicine, said to be precision medicine, within a knowledge economy in search of promising innovation.
This initiative is under the direction of Dr. Benoit Coulombe.
Additional information (+)